Drug Research
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Aurinia Pharmaceuticals Inc. announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza’s existing small molecule API facility in Visp, Switzerland. The dedicated facility (also referred...
Drug Research
Thermo Fisher Scientific Expands Clinical Supply Chain Services in Europe
To meet accelerating demand for robust clinical supply chain services throughout Europe, Thermo Fisher Scientific has expanded its pharma services footprint with two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany. The new sites will bring much-needed...
Clinical Trials
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, in markets accepting the CE Mark. Roche has also filed for Emergency Use...
Packaging & Labelling
UPS To Support Distribution Of Approved Vaccine As Part Of Operation Warp Speed
UPS announced its involvement and full support of distribution efforts for Pfizer-BioNTech’s COVID-19 vaccine as part of Operation Warp Speed. Pfizer’s and BioNTech’s vaccine, approved through a U.S. FDA EUA, is the first to be deployed in a months-long...
Packaging & Labelling
FedEx to Ship First Wave of COVID-19 Vaccines Across the United States
FedEx Express, a subsidiary of FedEx Corp. and the world’s largest express transportation company, announced that operations are in motion to transport its first shipments of COVID-19 vaccines.
Following the Food and Drug Administration’s approval of Emergency Use Authorization for...
Clinical Trials
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib as a Treatment for Patients with COVID-19 Associated Cytokine Storm
Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet...
Press Releases
Recipharm invests USD 2.5 million in clinical GMP capacity for active pharmaceutical ingredients
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced an investment and capacity expansion at its facility in Israel. This investment will support customers’ growing demand for cGMP clinical supply of active pharma ingredients (API) and intermediates and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read